As more manufactured cellular therapies move into clinical use, there is an increasing
call for cell culture media supplements that are of high quality, compatible with
different cell types, and not supply limited. Human platelet lysate (HPL) is one of
several supplements available for manufacturing cell products. Derived from multiple
platelet units, HPL contains the same types of growth factors and cytokines in FBS
and human AB serum at comparative levels. Despite the low risk with platelet units
screened and tested using the same criteria as transfusable blood, transmission of
infectious agents, notably viruses, remains a consideration for human platelet-derived
products such as HPL. Pooling platelet concentrates can improve HPL consistency and
performance, but increases the statistical risk of viral contamination.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
